Sino Biopharmaceutical (HKG:1177) presented the latest results of the phase III clinical study of its benmelstobart injection at the 2025 American Society of Clinical Oncology Annual Meeting, a Thursday Hong Kong bourse filing said.

The drug is being studied for use with or without anlotinib hydrochloride capsules as maintenance treatment for non-small cell lung cancer without progression following chemoradiotherapy.

The median progression-free survival of the arm of benmelstobart in combination with anlotinib was significantly prolonged with a 51% lower risk of disease progression or death, compared with the arm of the placebo.